Kartik Padh

Director of the BOD; President

With over 20 years of international experience in the biopharma industry in Asia-Pacific, Europe and USA, Mr. Padh has held multiple management and leadership positions in Quality and Compliance, Operations and Technology Transfer, Validation and Automation. He was previously Head of Quality / Head of Manufacturing at MSD Singapore; as Head of Manufacturing Quality at Samsung Biologics, helping to gain successful licensure of two DS and two DP facilities; and various technical and management positions in the industry including in Genentech.

Donald Palahnuk

Director of the BOD; CTO

With over 30 years of biotech experience, Mr. Palahnuk has demonstrated high-level leadership in process development, MST, technology transfer, and technical operations oversight. He founded and led MST or PD departments at Samsung Biologics, TopAlliance, ImClone/Eli Lilly, and Bio-Thera, where he managed TT and supported registration for ipilimumab, rituximab, nivolumab, and several other novel therapeutics. He also held engineering positions at global companies including Hoffmann-La Roche, Procter and Gamble, and Takeda. He has an M.S. in Chemical Engineering from Lehigh University.

George Siu

VP Quality and Compliance

With over 20 years of biotech and pharmaceutical experience, Mr. Siu has held leading positions in Quality Assurance and Quality Control at Baxter Biosciences, Amgen, and Samsung Biologics. He has lead teams in Quality Assurance, including: Quality Digital Transformation, Data Integrity, Quality Management Systems, and Quality Control. He has a proven track record in implementing industry leading and enhanced digital Quality systems and processes.

Jinliang Song

VP Procurement

Mr. Song boasts a distinguished career, having held key management positions in prominent steel companies, including Tangshan Ganglu Iron & Steel Co., Ltd., one of northern China’s largest steel enterprises based in Tangshan. In 2002, he co-founded Hebei Zhonggang Steel and Iron Co., Ltd in Yutian, China, where he served as the Chief Financial Officer. Mr. Song has held many executive management positions in large steel companies including one of the largest in Northern China, Tangshan Ganglu Iron & Steel Co., Ltd. He is also the co-founder and CFO of Hebei Zhonggang Steel and Iron Co., Ltd in Yutian, China, which achieved annual sales revenue over $400 million in 2009 and was awarded “The City’s Most Outstanding Enterprise,” “Green Enterprise,” and “Enterprise of Honor.”

Concurrently, Mr. Song strategically transitioned into the real estate sector, undertaking deliberate acquisitions of expansive land parcels and development rights in rural, undeveloped areas. A notable investment involved the majority development rights acquisition of Xiangyun Island, located on the Hebei province coastline, approximately a 3-hour drive from Beijing. This pivotal development right was subsequently integrated into CLB Investment Group, an entity co-founded by Mr. Song in 2005.

In 2008, Mr. Song played a crucial role in co-founding Langfang Shangcheng Real Estate Development Co., Ltd, directing its focus towards large-scale urban development projects in Langfang city, a thriving satellite town of Beijing, China. Under his leadership, the company successfully realized the development of an over 15 million square foot mixed-use complex, encompassing shopping centers, residential buildings, offices, and hospitality spaces. Mr. Song also spearheaded the acquisition of the Riverfront Garden Project in Shanghai, breaking ground in September 2013.

In that same transformative year of 2013, Mr. Song actively expanded CLB Investment Group’s real estate network to Los Angeles, New York, and other major U.S. real estate markets. Simultaneously, he led Langfang Shangcheng in making strides in the U.S. real estate market with a housing development project in North Dakota.

Mr. Song earned his junior college degree in construction from Xi’an Jiaotong University (Tangshan Campus). He pursued further studies in accounting and finance through Hunan University’s continuing education program. Mr. Song’s dedication to professional development is underscored by his qualification as a medium-level accountant in China, showcasing his expertise and proficiency in the financial domain.

Yih Horng Tan, PhD

VP Drug Product

Dr. Tan has extensive experiences in running large domestic and international technology transfer projects. He was previously Senior Manager of Drug Product Manufacturing Science and Technology at the BrammerBio part of Thermo Fisher Scientific; Senior Process Engineer at Lantheus Medical Imaging; Senior Research Scientist at Albany Molecular Research. He holds a B.S. in Chemistry from Acadia University, Ph.D. in Chemical Biology from University of California, Davis, and completed post-doctoral training at University of Missouri, St. Louis.

Harvey He, MBA

VP, CLB Shenzhen

With over 26 years of experience in the pharma and biotech industry, Mr. He has held senior management positions in various companies such as Pharmaron Biologics, WuXi Biologics, Fosun Pharma, Thermo Fisher Scientific and Abcam, in the US, Canada and China. Familiar with GMP regulations in China, Europe and the US, as well as quality systems. He holds a B.S. degree in microbiology from Shandong University and MBA from the University of Alabama.

Tim Calvert, PhD

VP International Markets

Dr. Calvert has more than 15 years of experience in leading delivery of integrated drug discovery & development solutions from virtual startups to global pharma, in both small and large molecule modalities. With a proven record of leadership and accomplishment, he was General Manager, Material and Structural Analysis at Thermo Fisher Scientific; VP at Abzena and Concept Life Sciences; Business Development Account Director at Catalent; and launched Lonza’s cell and gene therapy business in E.U. markets. He obtained his Ph.D. in Biotechnology from Glasgow Caledonian University.